Results 91 to 100 of about 4,836 (184)

50251 Efficacy of Risankizumab Versus Apremilast Among Patients with Scalp or Nail Psoriasis from the Phase 4 IMMpulse Study

Background: The phase-4, IMMpulse study (NCT04908475) has demonstrated superior efficacy and safety of risankizumab compared to apremilast in systemic-eligible adult patients with moderate plaque psoriasis (1). Methods: At baseline, 118 patients received
Pinter, Andreas, Stakias, Vassilis, Tyring, Stephen K, Stein-Gold, Linda, Papp, Kim A, Wu, Tianshuang, Pavlovsky, Lev, Hong, H. Chih-ho, Reich, Adam, Richter, Sven   +9 more
core  

Prescribing patterns and persistence of biological therapies for psoriasis management: a retrospective cohort study from Saudi Arabia

Journal of Dermatological Treatment
Background Biological therapies are effective for psoriasis, but patient responses vary, often requiring therapy switching or discontinuation.Objectives To identify physicians’ prescribing patterns of biological therapies at a referral tertiary center in
Ahmad Alamer, Wejdan Alyazidi, Saad Aldosari, Fatimah Mobarki, Sarah Almakki, Abdullah Alahmari, Mukhtar Alomar, Ziyad Almalki, Tuqa Alkaff, Mohammad Fazel   +9 more
doaj   +1 more source

Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies

RMD Open
Objective To assess the efficacy of long-term treatment with risankizumab across the updated Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) domains and key related conditions of psoriatic arthritis (PsA).Methods This post
Filip van den Bosch, Laure Gossec, Frank Behrens, Ricardo Blanco, Laura C Coates, Michael Chen, Linyu Shi, Alexis Ogdie, Roberto Ranza, Ralph Lippe, Ahmed M Soliman, Yael Klionsky, Derek Coombs, Jamie R Urbanik, Thomas Iyile   +14 more
doaj   +1 more source

Complete clearance of high-impact sites with risankizumab in patients with psoriasis: a 2-year real-world retrospective multicenter cohort study

Journal of Dermatological Treatment
Objectives Plaque psoriasis frequently involves high-impact anatomical sites such as the scalp, nails, and palmoplantar regions, which are associated with significant functional impairment and reduced quality of life.
Margarida Contente, Ana Luísa João, Martim Luz, Pedro Mendes-Bastos, Ângela Roda, Luiz Leite, Joana Valério, Ana Ferreirinha, Bárbara Leal, Maria João Paiva Lopes, Rita Pimenta, Paulo Ferreira, Tiago Torres   +12 more
doaj   +1 more source

Real-World Efficacy of IL-23 Inhibitors in Psoriasis Affecting High-Impact Areas: Indirect Comparison of Tildrakizumab 200 mg, Risankizumab, and Guselkumab—IL PSO (Italian Landscape Psoriasis)

Dermatology and Therapy
Introduction Psoriasis involving special or high-impact areas (scalp, nails, palms/soles, genitalia) is associated with a disproportionate functional and psychological burden that is often underestimated by conventional severity scores and remains ...
Emanuele Trovato, Alessandra Cartocci, Francesca Gaiani, Francesco Messina, Luca Mastorino, Nicole Macagno, Andrea Carugno, Marco Campoli, Maria Concetta Fargnoli, Viviana Lora, Agnese Rossi, Helena Gioacchini, Luca Potestio, Giovanni Marco D’Agostino, Martina Maurelli, Giampiero Girolomoni, Marco Romanelli, Valentina Dini, Francesco Loconsole, Francesca Satolli, Gianluca Pagnanelli, Claudia Lasagni, Andrea Michelerio, Martina Dragotto, Piergiorgio Malagoli, Nicola Zerbinati, Diego Orsini, Anna Campanati, Matteo Megna, Tommaso Bianchelli, for the Italian Landscape Group, Antonio Costanzo, Simone Ribero, Alessandra Narcisi   +33 more
doaj   +1 more source

Comparative safety profiles of risankizumab versus guselkumab: a pharmacovigilance study based on the FAERS database

Frontiers in Pharmacology
BackgroundRisankizumab and guselkumab are two leading interleukin-23 (IL-23) inhibitors for treating immune-mediated inflammatory diseases. While effective, a direct comparison of their real-world safety profiles is lacking.
Shiyi Wang, Yongyi Xu, Hangjuan Lin, Xudong Zhang, Jing Ding, Honggang Jiang, Yihong Fan, Changbo Sun   +7 more
doaj   +1 more source

Clinical insights into IL-23 inhibition: risankizumab for Crohn’s disease through a systematic review and meta-analysis of randomized controlled trials

Therapeutic Advances in Gastroenterology
Background and aims: Crohn’s disease is a chronic inflammatory disorder with rising global prevalence, marked by abdominal pain, diarrhea, and fatigue.
Po-Feng Huang, Tien-Yu Huang, Yi-Chiao Cheng, Peng-Jen Chen, Wei-Kuo Chang, Chao-Feng Chang   +5 more
doaj   +1 more source

Real-World Effectiveness and Safety of Risankizumab in Psoriasis: A Comprehensive Analysis from the Saudi Arabia Psoriasis Registry (PSORSA)

Dermatology and Therapy
Introduction Psoriasis is a chronic immune-mediated skin condition that has a substantial impact on patients’ quality of life. The Saudi Arabia Psoriasis Registry (PSORSA) was established to address long-term real-world data (RWD) on systemic and ...
Mohammed Ibrahim Fatani, Abdulaziz Madani, Fahad Alzuriqan, Abdullah Albadri, Ahmed Aljedai, Hajer Almudaiheem, Maysa Tariq Eshmawi   +6 more
doaj   +1 more source

PO:05:069 | Risankizumab efficacy in peripheral and axial involvement: monocentric experience

Reumatismo
Risankizumab, an anti–IL-23 monoclonal antibody, is approved for the treatment of peripheral psoriatic arthritis (PsA), and increasing evidence suggests its potential efficacy in patients with concurrent axial involvement.
Società Italiana di Reumatologia
doaj  

Real-world trajectories in psoriatic arthritis under risankizumab therapy

Therapeutic Advances in Musculoskeletal Disease
Background Risankizumab, a selective IL-23p19 inhibitor, has demonstrated efficacy in randomized clinical trials, but real-world data remain limited. Objectives To evaluate the real-world effectiveness and safety of risankizumab in PsA, and to identify ...
Saviana Gandolfo, Ilenia Pantano, Daniele Mauro, Anna Balato, Maurizio Caminiti, Eleonora Celletti, Maria Sole Chimenti, Antonio Ciancio, Luca Idolazzi, Matteo Megna, Giuseppa Pagano Mariano, Maura Raimondi, Flavia Riccio, Enrico Tirri, Alessandro Giunta, Paolo Gisondi, Giuseppe Argenziano, Antonio Costanzo, Carlo Selmi, Francesco Ciccia   +19 more
doaj   +1 more source